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Abstract
Background: In 2018, leukaemia accounted for 2.6% of all new cancers, it being the 13th most common cause of
cancer and the 10th most common cause of cancer death. Glucocorticoids are commonly used in lymphoid
leukaemia treatment, where they are cytotoxic. The aim of this review is to highlight ongoing research of steroid
use in myeloid leukaemias.
Main text: Glucocorticoids increase infection risks in acute myeloid leukaemia, but with adequate antifungal cover,
they can help in hyperleucocytic disease. They also show some benefits in sensitising multidrug-resistant AML cell
lines to cytotoxic agents, induce differentiation marker expression and can also induce CD38 expression, making
AML cells possible targets of daratumumab.
Cardiotonic steroids, like digitalis, are being recognised as sensitising AML cells to the chemotherapeutic effects of
many cytotoxic agents, primarily by inhibiting efflux pumps, thus minimising AML resistance.
Ecdysteroids enhance sensitivity in multidrug-resistant AML, but also in non-resistant AML cell lines, through
pathways including the activation of mitochondrial apoptosis. Their anti-apoptotic effects on non-malignant cell
lines help their target specificity. Sensitisation is chemotherapy-specific, enhancing the effects of doxorubicin and
tubulin inhibitors but increasing resistance to cisplatinum.
Short conclusion: Cardiotonic steroids and ecdysteroids both show chemosensitisation to the cytotoxic effects of
chemotherapy on AML cell lines. It is likely time to consider clinical trials to assess whether these, as well as
traditional glucocorticoids, can contribute to the AML armamentarium, particularly in chemo-resistant disease.
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Background
Leukaemia is a haematological malignancy which may
present either acutely or chronically and is broadly clas-
sified into lymphocytic and myelogenous types. Chronic
leukaemias typically progress slowly, unlike acute leukae-
mias, which require immediate treatment [1].
Acute lymphoblastic leukaemia (ALL) is commonly
treated with a combination of chemotherapeutic drugs
(such as vincristine and asparaginase) and steroids with
high dose dexamethasone used to overcome drug resist-
ance in T cell ALL and high-risk ALL [2]. Acute myeloid
leukaemia (AML), however, is not yet targeted by
steroids. We investigate ongoing research towards this
goal. Medically used steroids include glucocorticoids,
mineralocorticoids, and sex steroids. As well as naturally
occurring steroids, synthetic versions of all of these have
been developed [3]. The corticosteroids being discussed
in this literature review are prednisone and dexametha-
sone, both being synthetic glucocorticoids.
Due to the high tendency for leukaemic blasts to infil-
trate the cerebrospinal fluid (CSF) in ALL, certain earlier
treatment protocols for patients at high risk of central
nervous system (CNS) disease included the use of
prophylactic cranial irradiation. Since irradiation to the
CNS has a wide range of acute and chronic complica-
tions, a combination of chemotherapeutic drugs (such as
cytarabine and methotrexate) and glucocorticoids may
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be administered intrathecally instead [4]. In fact, prophy-
lactic cranial irradiation has nowadays been effectively
replaced with chemotherapy and dexamethasone [5].
Clinical trials comparing prednisone and dexametha-
sone revealed that dexamethasone achieved better CNS
control and less CNS relapse [6]. However, different
studies report more neuropsychological and general tox-
icity with dexamethasone and greater incidence of death
during induction, in patients receiving dexamethasone
compared to prednisone [2]. Incidence of infections in
patients receiving dexamethasone was also increased
compared to those receiving prednisone [2, 7].
A case-controlled study in acute T cell leukaemia
(ATL) patients being treated with chemotherapy alone,
chemotherapy and steroids, or steroids alone recom-
mended that they should also receive prophylactic treat-
ment for the fungus, Pneumocystis jiroveci, known to
cause Pneumocystis pneumonia [8]. Infections may also
occur due to adrenal insufficiency secondary to pro-
longed steroid use, also increasing ALL mortality. Thus,
certain studies recommend tapering off steroid dosage,
particularly with dexamethasone [9]. Genetic variation
may also affect the extent of adrenal suppression by ex-
ogenous steroids [10]. Moreover, the prolonged use of
glucocorticoids may lead to glucocorticoid resistance,
which is itself an adverse prognostic factor in cancer
treatment [2].
Occasionally, steroid administration may lead to
tumour lysis syndrome (TLS), an oncologic emergency
characterised by hyperuricemia, hyperkalemia, hyper-
phosphatemia, and hypocalcemia due to rapid lysis of
tumour cells [11, 12]. Steroid treatment may also be as-
sociated with leucocytosis [13].
An imbalance in the activation of mineralocorticoid
receptors (MR) and glucocorticoid receptors (GR) in the
brain seems to play a role in induced neuropsychological
side effects [10]. These behavioural and mood changes
may result in “steroid psychosis” [14, 15]. Interestingly,
in some studies, a negative impact was also noted on the
mental health of close relatives of ALL patients [15]. Se-
vere neurobehavioural side effects with dexamethasone
may be diminished by its discontinuation, or by replace-
ment with prednisone, the simultaneous administration
of hydrocortisone and even potassium supplements [10,
16, 17]. This review outlines ongoing investigation of the
potential uses of steroids in the treatment of AML, in-
cluding chemo-resistant disease.
Main text
Glucocorticoids in acute myeloid leukaemia
While glucocorticoids are established agents in the treat-
ment of lymphoblastic leukaemia, their use in myeloid
leukaemia is debatable [18]. Steroids are not included in
any standard treatment protocols for AML [19]. Health
professionals are reluctant to use glucocorticoids due to
an increased risk of invasive fungal infections, sterile site
infections, bacteraemia, sepsis, and death [18, 20]. More-
over, in vitro studies have reported that in some cases,
paediatric AML cells were prone to glucocorticoid-
induced proliferation as opposed to induced differenti-
ation [21]. If extrapolated to the in vivo situation, this
might increase the risk of relapse. However, the addition
of dexamethasone to intensive chemotherapy results in a
significant reduction in relapse and overall better sur-
vival rate in already hyperleucocytic AML patients [18].
In such cases, it is recommended that patients also re-
ceive prophylactic antifungal treatment to prevent
infections.
Glucocorticoids bind to GR in the cytoplasm, which
can then either homodimerise and bind DNA or remain
monomeric, acting independent of DNA binding. This
may alter certain transcriptomic programmes, inhibiting
the activity of transcription factors (such as AP-1 and
NF-κB) and/or by modulating the early inflammatory re-
sponse (which is associated with chemoresistance). Thus,
dexamethasone may sensitise AML stem cells to
chemotherapy-induced cell death, thereby limiting the
risk of leukaemic regrowth and relapse [18]. Glucocorti-
coids and other steroids, such as progesterone, may also
exert collateral sensitivity in multidrug resistance (MDR)
cell lines, which may help improve survival rates [22].
AML cells treated with dexamethasone were also shown
to express higher levels of the CD38 marker after 1 week
[18]. This increased CD38 expression could serve as a
positive prognostic factor in treatment, as it helps the
immune system to target the malignant cells. Apart from
this, since the monoclonal antibody daratumumab binds
to the CD38 protein, inducing malignant cell apoptosis,
dexamethasone can help provide a potential new cyto-
toxic therapy route [23]. Moreover, with long-term dexa-
methasone treatment, a greater amount of monocytic
CD11b/CD14-positive cells can be noted. This demon-
strates that dexamethasone also encourages differenti-
ation of AML cells, thus reducing the proliferating
leukaemia cell burden [18].
Corticosteroids have already been used to treat certain
complications that may be encountered during the ther-
apy of AML. In acute promyelocytic leukaemia (APL),
steroids are used in patients who develop differentiation
syndrome, an unpredictable, but frequent complication
of all-trans retinoic acid (ATRA) administration [24].
Cardiotonic steroids
Cardiotonic steroids (CS) are natural compounds which
are found in both the animal and plant kingdoms. They
have long been used in the medical field to treat heart-
related problems, namely heart failure and arrhythmias
[22]. The cytotoxic properties of CS were first
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recognised when higher plasma concentrations of digi-
toxin were correlated with lower risks of leukaemia and
urinary tract cancers [25]. A number of studies were
then conducted regarding the effects that CS have on
malignant cells. These drugs are capable of either bind-
ing to Na+/K+ ATPase pump [22] or inhibiting the ATP-
binding cassette sub-family B member 1 (ABCB1) trans-
porter (also known as P-glycoprotein) [25].
Genetic and epigenetic differences amongst various
cancer cells lead to the acquisition of drug resistance
[26]. Mechanisms of cancer resistance include increased
efflux of the drug from the cell and decreased cytosolic
intake of the drug. Other mechanisms include the inhib-
ition of the apoptotic pathways, as well as the activation
of cellular growth and DNA repair pathways. MDR cell
lines are capable of keeping intracellular drug concentra-
tions at very low levels by different mechanisms. Such
MDR cell lines have enhanced expression of ABCB1
transporters, which pump out chemotherapeutic drugs,
including anthracyclines, taxanes, and vinca alkaloids
[22, 27]. Inhibition of P-glycoprotein results in inhibition
of MDR, which leads to an overall better prognosis when
treating concomitantly with chemotherapy [25].
MDR cells have also altered expression of other mem-
brane proteins, including the Na+/ K+ ATPase pumps
and Na+/H+ exchanger. MDR cell lines typically have
downregulation of Na+/K+ ATPase pumps and upregula-
tion of the Na+/H+ exchangers. The latter results in an
increase in cellular pH, which is typically seen in malig-
nant cells. Moreover, downstream signalling pathways
associated with the Na+/K+ ATPase pumps are also
commonly deregulated. The administration of correct
doses of CS, such as ouabain and digitalis, will reverse
MDR and increase intracellular acidity, which suppresses
cancer cell growth [22].
Interestingly, the most potent CS compounds induce a
greater cytotoxic effect on resistant cell lines than on
normal, non-malignant white blood cells [22]. It is
hypothesised that CS induce apoptosis in malignant cells
through the phenomenon of collateral sensitivity due to
P-glycoprotein inhibition. Collateral inhibition explains
how a particular drug may exert greater cytotoxic effects
in more resistant leukaemic cell lines compared to other
cells. For example, with verapamil (a P-glycoprotein in-
hibitor), the rate at which this drug is removed from the
cell by P-glycoprotein in MDR cell lines is much faster
than in non-MDR cell lines. Pumping out verapamil
from within the cell consumes high amounts of adeno-
sine triphosphate (ATP), which has to be re-supplied via
oxidative phosphorylation. This in turn generates high
amounts of reactive oxygen species (ROS), which even-
tually leads to apoptosis [22].
A number of CS/CS derivatives have shown overall
promising results, attributed to their low-resistance
indices, when compared to the resistance indices of
other established chemotherapeutic agents. The resist-
ance index is a mathematical calculation which takes
into consideration the respective half maximal inhibitory
concentration (IC50) value of each drug in the resistant
cells and the sensitive ones [22, 25]. Therefore, CS may
possibly be considered in patients with leukaemias re-
sistant to multiple chemotherapeutic drugs.
To date, clinical trials have been carried out to exam-
ine the effectiveness of CS on solid tumours, where
mixed results were obtained [25]. In leukaemia, only
in vitro studies have been carried out so far. These have
shown promising results, but clinical trials are essential
to establish their suitability for inclusion in potential fu-
ture treatment regimens [22, 25].
Ecdysteroids
Ecdysteroids are a family of natural compounds, found
in different organisms, including insects, other arthro-
pods, and plants. In insects, they play a key hormonal
role in moulting and development. In plants, they serve
as protection from phytophagous animals. They have
also been identified in fungal extracts, but their role
there has not yet been deduced [28]. It is hypothesised
that these compounds are unable to interact with the
mammalian steroid-hormone receptors due to funda-
mental differences in their structure, polarity, bulk, and
shape [29].
Despite this, the addition of ecdysteroids/ecdysteroid
derivatives, namely 20-hydroxyecdysone; 20-
hydroxyecdysone 20,22-acetonide; 20-hydroxyecdysone
2,3;20,22-diacetonide, with various chemotherapeutic
agents, has yielded better results in vitro overall [28].
These ecdysteroids/ecdysteroid derivatives are known in-
hibitors of the ABCB1 transporter (similar to CS [25]).
However, besides yielding positive results on MDR-cell
lines, the least polar ecdysteroid derivatives also showed
positive outcomes on non-MDR cell lines. The IC50
values of the chemotherapeutic agents (doxorubicin,
paclitaxel, and vincristine) decreased considerably when
used simultaneously with ecdysteroids/ecdysteroid deriv-
atives. On the other hand, when used with cisplatin,
these same ecdysteroids/ecdysteroid derivatives caused
an increase in the IC50 of the same malignant cells. This
indicates that collaborative cytotoxicity does not always
occur and is probably dependent on the mechanism of
action of the particular chemotherapy, with alkylating-
like agents being rendered paradoxically less efficient.
Other studies suggest that the ecdysteroid, β-ecdysone
(20-hydroxyecdysone) derived from Helleborus niger (a
traditional medicinal plant native to large parts of Eur-
ope), targets the mitochondrial outer membrane perme-
abilisation pathway (MOMP), modulating the
mechanism of apoptosis. The BCL-2 family of proteins
Farrugia et al. Journal of the Egyptian National Cancer Institute            (2021) 33:7 Page 3 of 5
are regulators of apoptosis. It was noted that β-ecdysone
(20-hydroxyecdysone) counters the MOMP inhibition
pathway mediated by the anti-apoptotic BCL-2 protein.
Moreover, 20-hydroxyecdysone also stimulates CD2
presentation on T-lymphocytes and aids in the function
of the immune system. Since Helleborus niger has other
active components besides β-ecdysone (20-Hydroxyecdy-
sone), it cannot be concluded that the plant extracts’
apoptotic properties are solely the result of ecdysteroids
and this requires further studies [30].
In contrast to their pro-apoptotic effect on leukaemic
cells [30], ecdysteroids exert an anti-apoptotic effect on
non-cancerous cell lines. In this context, most refer to
the phosphatidylinositol-3-kinase/protein kinase B signal
transduction (PI3K/Akt) pathway, which is responsible
for the anti-apoptotic effects of ecdysteroids [29, 31].
Thus, ecdysteroids appear to specifically target neoplas-
tic cells and may yet be developed as an additional tool
in the clinical armamentarium.
To date, only in vitro studies of ecdysteroids have been
conducted in AML. Based on these encouraging results,
it is hoped that clinical trials will be developed in the
near future.
Conclusion
Glucocorticoids already play a major role in the treat-
ment of ALL but are being shown to be useful in certain
niche areas of treatment of AML. AML with hyperleuco-
cytosis or resistant to classical chemotherapy are some
of these. Glucocorticoids may also play a role in indu-
cing differentiation, making cells more susceptible to im-
mune targeting. Less classically recognised steroids, such
as CS and ecdysteroids, also appear to enhance the cyto-
toxicity of standard chemotherapy by inhibiting efflux
pumps or via other mechanisms, but this may be agent
specific in certain cases. Based on this interesting
in vitro data, it is surmised that clinical trials may soon
be proposed to assess whether these steroids can be used
in the clinic to treat certain types of AML. More re-
search in this area is required and to be encouraged.
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